一个有前景的领域：调节心血管疾病中血管平滑肌细胞向内皮细胞转分化的失衡。
A promising field: regulating imbalance of EndMT in cardiovascular diseases.
机构信息
Key Laboratory for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Institute of Cardiovascular Disease, University of South China, Hengyang, Hunan Province, China.
出版信息
Cell Cycle. 2021 Aug;20(15):1477-1486. doi: 10.1080/15384101.2021.1951939. Epub 2021 Jul 16.
Endothelial-mesenchymal transition (EndMT) is widely involved in the occurrence and development of cardiovascular diseases. Although there is no direct evidence, it is very promising as an effective target for the treatment of these diseases. Endothelial cells need to respond to the complex cardiovascular environment through EndMT, but sustained stimuli will cause the imbalance of EndMT. Blocking the signal transduction promoting EndMT is an effective method to control the imbalance of EndMT. In particular, we also discussed the potential role of endothelial cell apoptosis and autophagy in regulating the imbalance of EndMT. In addition, promoting mesenchymal-endothelial transformation (MEndT) is also a method to control the imbalance of EndMT. However, targeting EndMT to treat cardiovascular disease still faces many challenges. By reviewing the research progress of EndMT, we have put forward some insights and translated them into challenges and opportunities for new treatment strategies for cardiovascular diseases.
内皮-间充质转化（EndMT）广泛参与心血管疾病的发生和发展。虽然没有直接的证据，但它作为这些疾病治疗的有效靶点非常有前途。内皮细胞需要通过 EndMT 来应对复杂的心血管环境，但持续的刺激会导致 EndMT 的失衡。阻断促进 EndMT 的信号转导是控制 EndMT 失衡的有效方法。特别是，我们还讨论了内皮细胞凋亡和自噬在调节 EndMT 失衡中的潜在作用。此外，促进间充质-内皮转化（MEndT）也是控制 EndMT 失衡的一种方法。然而，针对 EndMT 治疗心血管疾病仍然面临许多挑战。通过回顾 EndMT 的研究进展，我们提出了一些见解，并将其转化为心血管疾病新治疗策略的挑战和机遇。
Zotero 插件